SLC2A1 and relapsing-remitting multiple sclerosis: Peripheral CD4+ T lymphocytes from RRMS patients were activated with anti-CD28.2 Abs with or without AS605240 class 1 PI3K inhibitor and the level of glycolysis (Figure 5a,b), the expression of Glut1 (Figure 5c) and of activation markers (Figure 5d), pro-inflammatory cytokine expression (Figure 5e–h) as well as c-myc (Figure 5i,l) were analyzed.